[1]李 冬,方长太,程高翔.双重血浆分子吸附模式人工肝在重症急性肝衰竭患者中的应用效果[J].医学信息,2022,35(09):147-150.[doi:10.3969/j.issn.1006-1959.2022.09.037]
　LI Dong,FANG Chang-tai,CHENG Gao-xiang.Application Effect of Dual Plasma Molecular Adsorption System Artificial Liver in Patients with Severe Acute Liver Failure[J].Medical Information,2022,35(09):147-150.[doi:10.3969/j.issn.1006-1959.2022.09.037]
点击复制

双重血浆分子吸附模式人工肝在重症急性肝衰竭患者中的应用效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年09期
页码:
147-150
栏目:
临床研究
出版日期:
2022-05-01

文章信息/Info

Title:
Application Effect of Dual Plasma Molecular Adsorption System Artificial Liver in Patients with Severe Acute Liver Failure
文章编号:
1006-1959（2022）09-0147-04
作者:
李 冬; 方长太; 程高翔
（安徽医科大学附属安庆医院重症医学科，安徽 安庆 246000）
Author(s):
LI Dong; FANG Chang-tai; CHENG Gao-xiang
(Department of Critical Medicine,Anqing Municipal Hospital Affiliated to Anhui Medical University,Anqing 246000,Anhui,China)
关键词:
双重血浆分子吸附; 血浆置换; 急性肝衰竭; 人工肝
Keywords:
Dual plasma molecular adsorption system; Plasma exchange; Acute liver failure; Artificial liver
分类号:
R846
DOI:
10.3969/j.issn.1006-1959.2022.09.037
文献标志码:
A
摘要:
目的 观察双重血浆分子吸附（DPMAS）模式人工肝对入住重症监护室（ICU）的急性肝衰竭患者的疗效。方法 选取2019年8月-2021年5月入住我院ICU的急性肝衰竭患者66例，根据治疗方法将其分为观察组（n=34）和对照组（n=32）。两组在综合内科保守治疗基础上，观察组患者接受DPMAS模式人工肝治疗，对照组患者采用血浆置换（PE）治疗。比较两组上机前后的血液检验参数（肝功能、凝血项、电解质、血常规、炎性指标、炎性介质）、临床疗效、不良反应、平均住院日和28 d生存率。结果 观察组上机治疗后TBIL、ALT、AST、WBC、炎性指标和炎性介质均较上机前下降，差异有统计学意义（P＜0．05）；对照组上机治疗后肝功能指标、炎性指标和炎性介质均较上机前下降，PTA比上机前升高，差异有统计学意义（P＜0.05）；两组ALB、PTA上机前后的变化率比较，差异有统计学意义（P＜0.05）；两组总有效率、平均住院日和28 d生存率比较，差异无统计学意义（P＞0.05）；观察组不良反应总发生率低于对照组（8.82% vs 37.50%），差异有统计学意义（P＜0.05）。结论 DMPAS与PE对急性肝衰竭患者都具有较好的疗效，但DPMAS治疗能克服PE治疗的局限性，有效改善急性肝衰竭患者的症状，提升救治成功率，安全性良好，可作为在血浆紧张情况下的人工肝治疗的一种优先选择。
Abstract:
Objective To observe the effect of dual plasma molecular adsorption system (DPMAS) artificial liver on patients with acute liver failure in intensive care unit (ICU).Methods A total of 66 patients with acute liver failure admitted to ICU of our hospital from August 2019 to May 2021 were selected and divided into observation group (n=34) and control group (n=32) according to treatment methods. On the basis of comprehensive medical conservative treatment, patients in the observation group received DPMAS artificial liver treatment, while patients in the control group received plasma exchange (PE) treatment. The blood test parameters (liver function, coagulation, electrolyte, blood routine, inflammatory indexes, inflammatory mediators), clinical efficacy, adverse reactions, average hospitalization days and 28-day survival rate were compared between the two groups before and after operation.Results TBIL, ALT, AST, WBC, inflammatory indexes and inflammatory mediators in the observation group after treatment were lower than those before treatment, and the difference was statistically significant (P<0.05). The liver function indexes, inflammatory indexes and inflammatory mediators in the control group after treatment were lower than those before treatment, while PTA was higher than that before treatment, and the difference was statistically significant (P<0.05). There was statistically significant difference in the change rates of ALB and PTA between the two groups before and after commissioning (P<0.05). There was no significant difference in the total effective rate, average length of stay and 28-day survival rate between the two groups (P>0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group (8.82% vs 37.50%), and the difference was statistically significant (P<0.05).Conclusion Both DMPAS and PE have good curative effect on patients with acute liver failure, but DPMAS treatment can overcome the limitations of PE treatment, effectively improve the symptoms of patients with acute liver failure, improve the success rate of treatment, and has good safety, which can be used as a preferred choice for artificial liver treatment under plasma tension.

参考文献/References:

[1]李会,苏海滨.《2020年美国重症医学会指南：重症监护室成人急性和慢加急性肝衰竭的管理》摘译[J].临床肝胆病杂志,2020,36(5):991-995.[2]中华医学会感染病学分会肝衰竭与人工肝学组.中华医学会肝病学分会重型肝病与人工肝学组肝衰竭诊治指南(2018年版)[J].临床肝胆病杂志,2019,35(1):38-44.[3]Stravitz RT,Kramer DJ.Management of acute liver failure[J].Nat Rev Gastroenterol Hepatol,2009,6(9):542-553.[4]周亚东,杨琳,韩秋风,等.组合型人工肝技术治疗中毒性肝功能衰竭的临床研究[J].中华劳动卫生职业病杂志,2017,35(1):51-53. [5]Villarreal JA,Sussman NL.Extracorporeal liver support in patients with acute liver failure[J].Tex Heart Inst J,2019,46(1):67-68.[6]中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝治疗肝衰竭指南(2016年版)[J].中华临床感染病杂志,2016,9(2):97-103.[7]Mckenzie TJ,Lillegard JB,Nyberg SL.Artifificial and bioartifificial liver support[J].Semin Liver Dis,2008,28(2):210-217.[8]CHen JJ,Huang JR,Yang Q,et al.Plasma exchange-centered artiifcial liver support system in hepatitis B virus-related acute-on-chronic liver failure:a nationwide prospective multicenter study in China[J].Hepatobiliary Pancreat Dis Int,2016,15(3):275-281.[9]Gan JH,Zhou XQ,Qin AL,et al.Hybrid artificial liver support system for treatment of severe liver failure[J].World J Gastroenterol,2005,11(6):890-894.[10]张斌,杨永耿,巩月英,等.双重血浆分子吸附治疗急性肝衰竭的临床应用[J].世界华人消化杂志,2015,23(29):4720-4724. [11]秦含玉,贾佳,李国福.双重血浆分子吸附系统治疗急性肝衰竭的临床研究[J].中华重症医学电子杂志,2018,4(1):31-35. [12]Zhou YD,Yang L,Han QF,et al.Clinical effect of combined artificial extracorporeal liver support therapy for toxic hepatic failure[J].Chinese Journal of Industrial Hygiene and Occupational Diseases,2017,35(1):51-53.[13]Witko-Sarsat V,Gausson V,Nguyen AT,et al.AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients[J].Kidney International,2003,64(1):82-91.[14]黄少珍,曾蕾,庞新华.高血压药物联合不同血液净化方式对维持血液透析患者预后的影响[J].中国医学工程,2017,25(8):72-75. [15]李小鹏,钟渊斌,张伦理.血液净化联合内科常规治疗与单纯药物治疗64例重症毒蕈中毒效果比较[J].中国肝脏病杂志(电子版),2013,5(4):50-54.[16]黄美金,卢燕薇,陈永鹏.乙肝肝衰竭短期预后预测因子分析及模型构建[J].广东医学,2013,34(16):2543-2546.[17]谭又文,叶云,姜林仙,等.血浆置换联合持续血液滤过对肝功能衰竭患者短期生存期的影响[J].中华传染病杂志,2014,32(4):243-246.

相似文献/References:

[1]张秀灵,牟春燕,李 武.非生物人工肝支持系统的临床应用现状及进展[J].医学信息,2018,31(02):40.[doi:10.3969/j.issn.1006-1959.2018.02.014]
　ZHANG Xiu-ling,MOU Chun-yan,LI Wu.Current Status and Progress of Clinical Application of Abiotic Artificial Liver Support System[J].Medical Information,2018,31(09):40.[doi:10.3969/j.issn.1006-1959.2018.02.014]
[2]金 英.血浆置换联合大剂量甲泼尼龙对特发性血小板减少性紫癜患者血小板相关免疫球蛋白及T细胞亚群的影响[J].医学信息,2022,35(09):131.[doi:10.3969/j.issn.1006-1959.2022.09.032]
　JIN Ying.Effect of Plasma Exchange Combined with High-dose Methylprednisolone on Platelet-related Immunoglobulin and T Cell Subsets in Patients with Idiopathic Thrombocytopenic Purpura[J].Medical Information,2022,35(09):131.[doi:10.3969/j.issn.1006-1959.2022.09.032]
[3]刘燕燕,曾万江,徐晓燕,等.产后并发血栓性血小板减少性紫癜1例报告及文献复习[J].医学信息,2019,32(09):189.[doi:10.3969/j.issn.1006-1959.2019.09.065]
[4]李 鑫,阙文君,余泽波.以冷凝集素综合征为首发表现的淋巴瘤1例[J].医学信息,2020,33(12):188.[doi:10.3969/j.issn.1006-1959.2020.12.064]
[5]郭 婷,王伟新,张丽丽.血浆置换联合分子吸附再循环系统治疗肝衰竭的疗效[J].医学信息,2020,33(24):104.[doi:10.3969/j.issn.1006-1959.2020.24.028]
　GUO Ting,WANG Wei-xin,ZHANG Li-li.The Effect of Plasma Exchange Combined with Molecular Adsorption Recirculation System in the Treatment of Liver Failure[J].Medical Information,2020,33(09):104.[doi:10.3969/j.issn.1006-1959.2020.24.028]
[6]周 雪,童春帆.血液成分单采和血浆置换治疗血液病的临床疗效观察[J].医学信息,2022,35(08):130.[doi:10.3969/j.issn.1006-1959.2022.08.033]
　ZHOU Xue,TONG Chun-fan.Clinical Effect of Single Blood Component Collection and Plasma Exchange in the Treatment of Hematologic Diseases[J].Medical Information,2022,35(09):130.[doi:10.3969/j.issn.1006-1959.2022.08.033]

更新日期/Last Update: 1900-01-01